Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL). Treat and ...

New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

Current and emerging treatments for relapsed or refractory CLL show promise, with outcomes expected to improve beyond current data. Treatment responses in CLL can last for years, especially in ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.